ReviewThe estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance
Highlights
► We modeled deaths averted in persons vaccinated in 73 GAVI-eligible countries. ► Projected use of nine antigens during 2011–2020 is expected to avert 10 million deaths. ► Routine and supplemental measles vaccination is expected to avert an additional 13 million deaths. ► Most deaths averted will be in Africa and Southeast Asia, regions with high mortality.
Introduction
In 2008, the GAVI Alliance began work to estimate the impact of vaccination in countries eligible for support. Initial estimates relied on vaccine-specific estimates of the average number of deaths averted per 1000 persons vaccinated in GAVI-eligible countries, multiplied by forecast numbers of persons vaccinated. Estimates of the number of deaths averted per 1000 persons vaccinated were derived from published and unpublished studies, including vaccine trials and modeled impact estimates [1], [2]. While conceptually simple, the utility of this approach was limited because each derived estimate of the number of deaths averted per 1000 persons vaccinated was specific to a specific time period, target population, and vaccination strategy.
In August–December 2011, we updated the impact estimates using more refined modeling approaches, where available, and updated vaccine demand forecasts. Although the primary purpose of this exercise was to estimate the impact of GAVIs vaccine support, mortality in the 73 GAVI-eligible countries accounts for 94 percent of all deaths and 97 percent of deaths in children under five years old projected to occur during 2011–2020 in countries classified by the World Bank as low- or lower–middle-income economies [3]. Thus, the results of our analyses were used as a starting point for work to estimate the impact and economic benefits of the 2011–2020 Global Vaccine Action Plan [4].
This report summarizes the methods used to derive estimates of deaths averted in persons projected to be vaccinated during 2011–2020 in 73 GAVI-supported countries, presents the results of these analyses, and discusses limitations of the estimates, including potential biases. Work to validate key model assumptions and refine the estimates is ongoing. It is anticipated that subsequent analyses will be extended to include additional vaccines, morbidity impacts, and economic benefits.
Section snippets
Methods
The expected number of deaths averted in persons projected to be vaccinated during 2011–2020 in 73 countries supported by the GAVI Alliance was estimated for hepatitis B, yellow fever 17D, conjugate Haemophilus influenzae type B (Hib), conjugate Streptococcus pneumoniae, rotavirus, conjugate N. meningitidis serogroup A, live attenuated Japanese encephalitis, human papillomavirus types 16 and 18, rubella, and measles-containing vaccines. All 73 study countries will be receiving direct financial
Results
The cumulative numbers of countries projected to have introduced hepatitis B, H. influenzae type B (Hib), S. pneumoniae, rotavirus, rubella, human papillomavirus, yellow fever, N. meningitidis serogroup A, second-dose measles, and Japanese encephalitis vaccines are shown by year for the period 2011–2020 in Fig. 1. By 2020, all or nearly all GAVI-eligible countries with endemic disease are projected to have introduced hepatitis B, Hib, pneumococcal, rotavirus, rubella, yellow fever, conjugate N.
Discussion
This study demonstrates that vaccination in 73 GAVI-eligible countries during 2011–2020 is expected to have substantial health impacts, with the largest number of deaths averted occurring in Africa and Southeast Asia, the two regions with the highest mortality burden. Due to time constraints and lack of suitable models, we did not include the impact of all vaccines that are part of existing country immunization programs in these countries, or the impact of all vaccines likely to become
Conflict of interest
The authors confirm that they have no conflict of interest.
References (81)
- et al.
Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates
Lancet
(2009) - et al.
Global, regional, and national causes of child mortality in 2008: a systematic analysis
Lancet
(2010) - et al.
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Lancet
(2009) - et al.
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
Vaccine
(2008) - et al.
Cost-effectiveness of HPV 16 18 vaccination in Brazil
Vaccine
(2007) - et al.
Mathematical models of cervical cancer prevention in Latin America and the Caribbean
Vaccine
(2008) - et al.
Mathematical models of cervical cancer prevention in the Asia Pacific region
Vaccine
(2008) - et al.
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Lancet Oncol
(2010) - et al.
A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia
Vaccine
(2010) - et al.
Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case–control study in Nepalese children 5 years after immunization
Vaccine
(2007)
The predicted impact of private sector MMR vaccination on the burden of congenital rubella syndrome
Vaccine
Consequences of confirmed maternal rubella at successive stages of pregnancy
Lancet
Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children
Vaccine
Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data
Lancet
Efficacy and safety of a modified killed whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised double-blind, placebo-controlled trial
Lancet
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam
Lancet
Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial
Lancet
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data
Lancet Infect Dis
Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data
Lancet
Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000
Lancet
Estimates of world-wide distribution of child deaths from acute respiratory infections
Lancet Infect Dis
Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011
Curr Opin Virol
GAVI vaccine portfolio metrics analysis. Input assumptions – board paper case
Forecasting the impact of GAVI Alliance vaccine support using the long range cost and impact model: methods and limitations
World population prospects, the 2010 revision
Global Vaccine Action Plan
Vaccine
Immunization summary
A mathematical model to estimate global hepatitis B disease burden and vaccination impact
Int J Epidemiol
Methods used in the Lives Saved Tool (LiST)
BMC Public Health
The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality
Int J Epidemiol
Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems
Int J Epidemiol
Estimating child mortality due to diarrhoea in developing countries
Bull World Health Organ
Rotavirus and severe childhood diarrhea
Emerg Infect Dis
Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size
BMC Public Health
Effect of rotavirus vaccination on death from childhood diarrhea in Mexico
N Engl J Med
Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis
PLoS Med
Multiparameter calibration of a natural history model of cervical cancer
Am J Epidemiol
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting
Br J Cancer
Cost-effectiveness of cervical cancer screening in five developing countries
N Engl J Med
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa
Int J Cancer
Cited by (115)
Determinants of papillomavirus vaccination in Mayotte: A qualitative study among general practitioners
2024, Gynecologie Obstetrique Fertilite et SenologieGlobal, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
2022, The Lancet Gastroenterology and HepatologyVaccine human clinical trial
2022, System Vaccinology: The History, the Translational Challenges and the Future
- 1
Current address: GAVI Alliance, Geneva, Switzerland.
- 2
Current address: Management Sciences for Health, Arlington, VA, United States.